Common side effects of anti-EGFR therapy: acneform rash

Seminars in Oncology Nursing
Rebecca Sipples

Abstract

To review the general toxicity profile of EGFR-targeted therapies and the management of the most common side effect, skin toxicity. Research articles. The most common side effect of anti-EGFR therapy is skin toxicity, which is generally mild to moderate, but may be severe in up to 18% of patients. Appearance of more severe rash has been correlated with better treatment outcomes. Skin toxicity is generally manageable with standard topical or systemic antibiotics and anti-inflammatory agents. Rash does not warrant treatment discontinuation; however, when using TKIs, the combination of rash and severe diarrhea may require treatment cessation. Patients and nurses need to be well informed about the expected side effects of anti-EGFR therapy and appropriate management techniques. Patient education prior to beginning therapy and proactive intervention at the first signs of skin toxicity are key to successful management.

References

Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Nov 1, 2000·Cell·J Schlessinger
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan AlbanellJose Baselga
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin H CohenRichard Pazdur
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe GiacconeDavid H Johnson
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid H Johnson
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
May 4, 2004·The Lancet Oncology·Marion Harris
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Román Pérez-SolerPhilip Bonomi

❮ Previous
Next ❯

Citations

Jun 9, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yun-wu ZhangHuaxi Xu
Aug 3, 2014·Seminars in Oncology Nursing·Beth Eaby-Sandy, Kathy Lynch
Jul 9, 2009·Journal of Oncology·Monica GiovanniniEugenio Villa
Apr 21, 2011·Current Oncology·N Mittmann, S J Seung
May 4, 2012·Archives of Dermatological Research·Annika SääfMaria Bradley
Jan 11, 2012·European Journal of Clinical Pharmacology·Shoude ZhangBeibei Yang
Nov 13, 2015·Expert Review of Clinical Pharmacology·Qi Zhang, Yi-Long Wu
Mar 21, 2007·Expert Opinion on Drug Safety·M Wasif Saif, Richard Kim
Aug 7, 2012·Pathologie-biologie·K BouzidM Marty
Jun 29, 2010·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Jan Ouwerkerk, Christine Boers-Doets
Sep 2, 2006·Clinical Colorectal Cancer·Mohammad Wasif Saif, Michael Cohenuram
Jan 26, 2008·Seminars in Oncology Nursing·Susan Moore
Dec 17, 2008·Dermatologic Therapy·Annalisa PatriziIria Neri
Dec 17, 2014·Cancer Medicine·Garif Yalak, Viola Vogel
Mar 31, 2010·Clinical Journal of Oncology Nursing·Cynthia Frankel, Frances M Palmieri
Feb 2, 2010·Clinical Journal of Oncology Nursing·Pamela Hallquist Viale
Sep 27, 2016·Clinical Journal of Oncology Nursing·Martin WallnerHanna Mayer
Aug 13, 2015·Cancers·Guofeng Xie, Jean-Pierre Raufman
Feb 10, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lei ChenColeman K Obasaju
Oct 24, 2007·Journal of the National Cancer Institute. Monographs·Charles S Cleeland
Mar 2, 2017·American Journal of Clinical Dermatology·Priyanka VedakDaniela Kroshinsky
Nov 15, 2017·JBI Database of Systematic Reviews and Implementation Reports·Xiaolu GuoZhenqi Lu
Aug 15, 2009·The Oncologist·Nicholas ThatcherUNKNOWN U.K. Erlotinib Skin Toxicity Management Consensus Group
Nov 9, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Bernd TischerMario E Lacouture
May 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura K van DijkJohan Bussink
Jun 20, 2021·Cancer Research·Li-Chung TsaoZachary C Hartman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.